Altimmune, Inc. (NASDAQ:ALT) Receives $17.17 Average PT from Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $17.1667.

A number of brokerages have recently commented on ALT. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Barclays assumed coverage on shares of Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target for the company. Citizens Jmp reduced their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th.

Altimmune Stock Performance

NASDAQ:ALT opened at $4.53 on Wednesday. Altimmune has a 52 week low of $2.90 and a 52 week high of $7.73. The company has a fifty day simple moving average of $4.62 and a two-hundred day simple moving average of $4.22. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. The company has a market cap of $511.12 million, a price-to-earnings ratio of -4.23 and a beta of 0.09.

Insider Activity at Altimmune

In related news, Director Jerome Benedict Durso bought 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average cost of $4.13 per share, with a total value of $51,625.00. Following the transaction, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Gill purchased 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were bought at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares in the company, valued at $51,250. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 30,527 shares of company stock valued at $125,278. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Altimmune

Hedge funds have recently made changes to their positions in the company. CreativeOne Wealth LLC purchased a new stake in shares of Altimmune in the 4th quarter valued at about $38,000. Marshall Wace LLP acquired a new position in Altimmune during the fourth quarter worth approximately $3,331,000. Stifel Financial Corp increased its position in Altimmune by 104.3% during the fourth quarter. Stifel Financial Corp now owns 123,416 shares of the company’s stock worth $446,000 after buying an additional 63,005 shares during the period. Schroder Investment Management Group purchased a new stake in Altimmune in the fourth quarter valued at approximately $1,693,000. Finally, Rafferty Asset Management LLC boosted its holdings in shares of Altimmune by 25.3% in the fourth quarter. Rafferty Asset Management LLC now owns 195,766 shares of the company’s stock valued at $707,000 after acquiring an additional 39,572 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.